Acrivon - ACRV Net earnings per one share for the last twelve months

Acrivon Therapeutics (ACRV) faces stringent FDA oversight and high patent barriers in the field of personalized tumor treatment. This daily price chart for the company on the GURU.Markets platform reflects an EPS (TTM) of 15.80. The enterprise develops predictive systems for precise drug selection, leveraging capital support. However, its narrow specialization in proteomic drug discovery entails significant binary risks.
Financial and market metric breakdowns for Acrivon Therapeutics (ACRV)

Acrivon Therapeutics (ACRV) minimizes operational risks by employing precision patient selection for the therapy of various solid tumors in oncology. The earnings per share (EPS) trend, recalculated based on 10-Q reports, reflects the business's actual trajectory, while historical YoY EPS growth over the last 12 months helps identify asset overheating and avoid buying at the peak of inflated expectations.